Drug intelligence / Profile preview

bifidobacterium longum L693

Development stage: Preclinical
Lead developer: Hebei Inatural Biotech
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium longum L693 is a specific probiotic strain developed by Hebei Inatural Biotech. It is categorized as a food ingredient and a probiotic/fermentation strain within the company's product pipeline. As a member of the Bifidobacterium genus, L693 is intended to support gut health and microbiome balance. While specific clinical mechanisms or primary indications are not detailed on the developer's site, Bifidobacterium longum strains are generally recognized for their ability to modulate the intestinal microbiota, enhance the gut barrier, and potentially provide immunomodulatory effects through the production of metabolites such as short-chain fatty acids.

Other names: Bifidobacterium longum L693

Beyond the preview

Go deeper on bifidobacterium longum L693.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium longum L693.

Explore the full profile